Archived explainer. For the current picture see today's HUM page.
HUMANA INC (HUM) is up +11.56% in the latest session. Our newswire has captured 5 stories on HUM across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100).
Humana shares surged 11.56% to close at $431.87, driven by a significant improvement in its Medicare Advantage quality metrics. The company announced that 95% of its Medicare Advantage members are now enrolled in plans rated at least four stars for 2027. This upgrade is expected to make a larger portion of its membership eligible for quality-related bonus payments, directly supporting future profit margins.
The primary catalyst for the rally was the disclosure of the 2027 star ratings, which marked a notable improvement for the health insurer. Analysts noted that this progress could alleviate some valuation concerns, as higher star ratings typically correlate with better reimbursement rates and lower administrative costs. While some commentary suggested that efficiency gains and better ratings do not fully erase margin pressures, the market responded positively to the potential for improved cash flow.
Barclays maintained an Overweight rating on Humana and raised its price target to $582. Similarly, Oppenheimer maintained an Outperform rating and raised its price target to $475. These moves reflect a broader consensus that the company's operational improvements are translating into tangible financial benefits. The stock’s performance also contributed to a broader rally in the healthcare sector, with peers like Moderna and Lumentum also hitting 52-week highs during the same period.
Humana’s market capitalization stands at $51.9 billion, with a trailing twelve-month revenue growth of 18.3%. The company currently trades at a price-to-earnings ratio of 40.8, with a net margin of 0.9% and a beta of 0.74. The stock is trading near the top of its 52-week range, which spans from $163.11 to $456.50. Over the last eight sessions, the stock has climbed 12.9%, moving from $381.57 to $430.82.
Recent congressional filings show mixed activity, with one buy and one sell recorded in the last 90 days. Donald J. Trump sold between $15,001 and $50,000 on July 8, 2026, while Senator Alan Armstrong bought between $1,001 and $15,000 on March 27, 2026. Social media activity remains low, with only two posts in the past seven days and one Reddit mention, suggesting the move is driven more by fundamental news than retail speculation.
Investors will monitor how the improved star ratings impact quarterly earnings and whether the raised price targets from major banks are met in the coming months. The stock’s proximity to its 52-week high will be a key indicator of continued momentum.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Humana said 95% of its Medicare Advantage members are enrolled in plans rated at least four stars for 2027, an improvement that could make more of its membership eligible for quality-related bonus payments.
The rallies highlighted growth opportunities across biotechnology, health insurance and optical technology.
Humana said 95% of its Medicare Advantage members are enrolled in plans rated at least four stars for 2027, an improvement that could make more of its membership eligible for quality-related bonus payments.
Humana stock: efficiency gains and better Star Ratings, but margins/cash flow pressured. Click for more on HUM stock.
Humana shares rallied, adding more than 10%, after the health insurer said 95% of its Medicare Advantage members are enrolled in plans rated at least four stars for 2027, boding well for the company's profit margins.
More on HUM: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier HUM move explainers: 2026-10-12 · 2026-10-09 · 2026-09-25